The paper links blood–brain barrier disruption with gut microbiota dysbiosis in Parkinson’s disease, proposing a gut–brain axis association between peripheral microbial changes and central barrier integrity.

It points to potentially targetable mechanisms (microbiome modulation and BBB-protective strategies) and biomarker opportunities relevant to PD therapeutics, though lack of abstract/details limits immediate actionability.